In all CRC cells used for cell viability assays, combined treatment with DKC1125 with 5-FU or oxaliplatin restored the IC50 of 5-FU or oxaliplatin in KITENIN-overexpressing cells and increased the sensitivity to these agents as a function of DKC1125 concentration (Fig. 7a, Additional file 5: Fig. S5). Here, VANGL1 is linked to colorectal carcinoma.